Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy Kharlip J; Salvatori R; Yenokyan G; Wand GSJ Clin Endocrinol Metab 2009[Jul]; 94 (7): 2428-36CONTEXT: Recurrence of hyperprolactinemia after cabergoline withdrawal ranges widely from 36 to 80%. The Pituitary Society recommends withdrawal of cabergoline in selected patients. OBJECTIVE: Our aim was to evaluate recurrence of hyperprolactinemia in patients meeting The Pituitary Society guidelines. DESIGN: Patients were followed from the date of discontinuation to either relapse of hyperprolactinemia or the day of last prolactin test. SETTING: We conducted the study at an academic medical center. PATIENTS: Forty-six patients meeting Pituitary Society criteria (normoprolactinemic and with tumor volume reduction after 2 or more years of treatment) participated in the study. INTERVENTIONS: After withdrawal, if prolactin returned above reference range, another measurement was obtained within 1 month, symptoms were assessed by questionnaire, and magnetic resonance imaging was performed. MAIN OUTCOME MEASURES: We measured risk of and time to recurrence estimates as well as clinical predictors of recurrence. RESULTS: Mean age of patients was 50 +/- 13 yr, and 70% were women. Thirty-one patients had microprolactinomas, 11 had macroprolactinomas, and four had nontumoral hyperprolactinemia. The overall recurrence was 54%, and the estimated risk of recurrence by 18 months was 63%. The median time to recurrence was 3 months (range, 1-18 months), with 91% of recurrences occurring within 1 yr after discontinuation. Size of tumor remnant prior to withdrawal predicted recurrence [18% increase in risk for each millimeter (95% confidence interval, 3-35; P = 0.017)]. None of the tumors enlarged in the patients experiencing recurrence, and 28% had symptoms of hypogonadism. CONCLUSIONS: Cabergoline withdrawal is practical and safe in a subset of patients as defined by The Pituitary Society guidelines; however, the average risk of long-term recurrence in our study was over 60%. Close follow-up remains important, especially within the first year.|*Withholding Treatment[MESH]|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Antineoplastic Agents/adverse effects/therapeutic use[MESH]|Cabergoline[MESH]|Ergolines/adverse effects/*therapeutic use[MESH]|Female[MESH]|Humans[MESH]|Hyperprolactinemia/diagnosis/*drug therapy/epidemiology/etiology[MESH]|Male[MESH]|Middle Aged[MESH]|Pituitary Neoplasms/complications/drug therapy/pathology[MESH]|Pregnancy[MESH]|Pregnancy Complications, Neoplastic/drug therapy[MESH]|Prognosis[MESH]|Prolactinoma/complications/drug therapy/pathology[MESH]|Recurrence[MESH]|Retrospective Studies[MESH]|Time Factors[MESH]|Young Adult[MESH] |